Literature DB >> 9661994

Indomethacin reverses the microglial response to amyloid beta-protein.

E E Netland1, J L Newton, R E Majocha, B A Tate.   

Abstract

Alzheimer's disease (AD) brains display intense microglial immunoreactivity in the area of senile plaques, suggesting that amyloid beta-protein may stimulate microglial infiltration. The activated microglia may modulate an immune response in the brain. Non-steroidal anti-inflammatory drugs (NSAIDs) are candidate therapeutics for AD because their effects on immune system components may influence the course of the disease. The present study examined the effects of an NSAID (indomethacin) on amyloid beta-protein-induced microglial infiltration. Amyloid beta-protein was chronically infused into rat lateral ventricles for 2 weeks. Extracellular amyloid beta-protein deposited along the lining and diffused into the tissue surrounding the lateral ventricle. Immunocytochemical staining showed that animals receiving amyloid beta-protein exhibited dramatic microglial response when compared to vehicle-infused rats. Activated microglia surrounded immunopositive amyloid beta-protein deposits, but this response was significantly attenuated in animals receiving either concurrent i.c.v. or subcutaneous (s.c.) treatment with indomethacin. These results suggest that chronic amyloid beta-protein infusion induces the proliferation of activated microglia and that indomethacin may be an effective treatment for inhibiting microglial proliferation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9661994     DOI: 10.1016/s0197-4580(98)00047-5

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  21 in total

Review 1.  Adaptive immune regulation of glial homeostasis as an immunization strategy for neurodegenerative diseases.

Authors:  Lisa M Kosloski; Duy M Ha; Jessica A L Hutter; David K Stone; Michael R Pichler; Ashley D Reynolds; Howard E Gendelman; R Lee Mosley
Journal:  J Neurochem       Date:  2010-05-26       Impact factor: 5.372

2.  Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation.

Authors:  Belén G Ramírez; Cristina Blázquez; Teresa Gómez del Pulgar; Manuel Guzmán; María L de Ceballos
Journal:  J Neurosci       Date:  2005-02-23       Impact factor: 6.167

3.  A Precision Medicine Model for Targeted NSAID Therapy in Alzheimer's Disease.

Authors:  Sid E O'Bryant; Fan Zhang; Leigh A Johnson; James Hall; Melissa Edwards; Paula Grammas; Esther Oh; Constantine G Lyketsos; Robert A Rissman
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

Review 4.  Inflammation and Alzheimer's disease.

Authors:  H Akiyama; S Barger; S Barnum; B Bradt; J Bauer; G M Cole; N R Cooper; P Eikelenboom; M Emmerling; B L Fiebich; C E Finch; S Frautschy; W S Griffin; H Hampel; M Hull; G Landreth; L Lue; R Mrak; I R Mackenzie; P L McGeer; M K O'Banion; J Pachter; G Pasinetti; C Plata-Salaman; J Rogers; R Rydel; Y Shen; W Streit; R Strohmeyer; I Tooyoma; F L Van Muiswinkel; R Veerhuis; D Walker; S Webster; B Wegrzyniak; G Wenk; T Wyss-Coray
Journal:  Neurobiol Aging       Date:  2000 May-Jun       Impact factor: 4.673

5.  Cyclooxygenase (COX)-1 activity precedes the COX-2 induction in Aβ-induced neuroinflammation.

Authors:  Leila Dargahi; Shiva Nasiraei-Moghadam; Azadeh Abdi; Leila Khalaj; Fatemeh Moradi; Abolhassan Ahmadiani
Journal:  J Mol Neurosci       Date:  2010-06-12       Impact factor: 3.444

Review 6.  Role of the immune system in the pathogenesis, prevention and treatment of Alzheimer's disease.

Authors:  Imrich Blasko; Beatrix Grubeck-Loebenstein
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

7.  Genistein improves neuropathology and corrects behaviour in a mouse model of neurodegenerative metabolic disease.

Authors:  Marcelina Malinowska; Fiona L Wilkinson; Kia J Langford-Smith; Alex Langford-Smith; Jillian R Brown; Brett E Crawford; Marie T Vanier; Grzegorz Grynkiewicz; Rob F Wynn; J Ed Wraith; Grzegorz Wegrzyn; Brian W Bigger
Journal:  PLoS One       Date:  2010-12-01       Impact factor: 3.240

8.  In silico theoretical molecular modeling for Alzheimer's disease: the nicotine-curcumin paradigm in neuroprotection and neurotherapy.

Authors:  Pradeep Kumar; Viness Pillay; Yahya E Choonara; Girish Modi; Dinesh Naidoo; Lisa C du Toit
Journal:  Int J Mol Sci       Date:  2011-01-19       Impact factor: 5.923

Review 9.  Drug development for Alzheimer's disease: where are we now and where are we headed?

Authors:  Marwan N Sabbagh
Journal:  Am J Geriatr Pharmacother       Date:  2009-06

Review 10.  Indomethacin for the treatment of Alzheimer's disease patients.

Authors:  N Tabet; H Feldman
Journal:  Cochrane Database Syst Rev       Date:  2002
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.